Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 6, 2014Clinical Cancer ResearchOpen Access

Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVarsha GandhiThe University of Texas MD Anderson Cancer CenterWPWilliam PlunkettThe University of Texas MD Anderson Cancer Center
Jorge E. Cortés
Jorge E. CortésAugusta University Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gandhi et al. (2014) studied this question.

synapsesocial.com/papers/6a195ea0a0353395e9583edbhttps://doi.org/10.1158/1078-0432.ccr-13-1283
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?1988 · 39 citations
  2. 2Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase2003 · 66 citations
  3. 3Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia2000 · 94 citations